Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NETWORK 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 16Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Smoldering Multiple Myeloma 1Plasmablastic Lymphoma 1Lymphoma 1Immunoglobulin Light-chain Amyloidosis 1Disease 1

Interventions

Cyclophosphamide 3carfilzomib 2Dexamethasone 2deltacortene 1daratumumab 1Melphalan 1Magnetic Resonance Spectroscopy 1Calcium Dobesilate 1Bortezomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Disease × daratumumab × Clear all
NCT03896737 2025-08-11

Daratumumab-bortezomib-dexamethasone (Dara-VCd) vs Bortezomib-Thalidomide-Dexamethasone (VTd), Then Maintenance With Ixazomib (IXA) or IXA-Dara

European Myeloma Network B.V.

Phase 2 Active not recruiting
401 enrolled
Plasma cell

Disease, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡